Headache News

Older adults recently diagnosed with migraine were more than three times likely to be involved in a motor vehicle crash within a year compared with those who never had a migraine diagnosis, according to researchers.

Performance Vision Technologies has launched Altius advanced performance-tinted contact lenses, the second generation to Nike MaxSight, in the U.S. and select international markets.

Among seven classes and 25 individual medications, triptans, ergots and anti-emetics were the most effective acute treatments for individuals with migraine, according to research published in Neurology.

Treatment with 100 mg ubrogepant was effective at curbing migraine attacks when administered during the prodromal phase compared with placebo, according to research from The Lancet.

Ajovy significantly reduced depression symptoms and monthly migraine days in a phase 4 study, with clinically meaningful improvements in disability outcomes, manufacturer Teva Pharmaceuticals announced in a press release.

An Illinois-based neuro tech company has announced the reception of a multimillion-dollar grant to support a post-stroke recovery study at the Cleveland Clinic with its novel micro-neuromodulation platform.

Peer victimization and suicidality were associated with higher headache frequency in adolescents, while the association between headache and gender diversity weakened after controlling for other factors, according to research in Neurology.

Treatment with atogepant at 30 mg and 60 mg reduced mean monthly migraine days over 12 weeks compared with placebo, while showing good safety and tolerability profiles, according to research published in the Lancet Neurology.

AUSTIN, Texas — More than 80% of those dealing with migraine or severe headaches reported cognitive impairment, with the most common being concentration difficulty, according to a presenter at the American Headache Society annual meeting.

A systematic literature review determined that various classes of blood pressure-lowering medication reduced frequency of migraine days per month compared with placebo, according to a study published in Cephalalgia.